A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

NCT07172919 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: Sotorasib
DRUG: Panitumumab

Sponsor

Amgen